Aviva’s Integra LifeSciences IART Stock Holding History

Aviva’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,000	Closed	-$248K	–	776
2016 Q3	$248K	Buy	+6,000	New	+$251K	﹤0.01%	776

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Aviva's IART Position: Q4 2016 in Review

Aviva sold out of Integra LifeSciences (IART) in Q4 2016, closing a stake of 6,000 shares — an estimated $248K sold.

Aviva first reported a position in IART in Q3 2016 and held it in 1 quarter. The position peaked at $248K in Q3 2016. 223 funds tracked by Wall St. Rank hold IART as of Q4 2016.

Aviva reported no remaining Integra LifeSciences position as of Q4 2016 after selling out during the quarter.
Aviva sold 6,000 Integra LifeSciences shares in Q4 2016, an estimated $248K.
Aviva first reported a position in Integra LifeSciences in Q3 2016 and held it in 1 quarter.
Aviva's Integra LifeSciences position peaked at $248K in Q3 2016.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2016.

Based on Aviva's 13F filing for Q4 2016, filed 13 Feb 2017.